The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy; however, CLL is still an incurable disease with resistance to therapy developing in a majority of patients. This Review summarizes the progress made in understanding the biological basis of CLL pathogenesis and other aspects of CLL biology, and describes novel treatment strategies that have also been exploited in current clinical trials.
- Lisa Pleyer
- Alexander Egle
- Richard Greil
